Q3 2025 Viking Therapeutics Inc Earnings Call Transcript
Key Points
- Viking Therapeutics Inc (VKTX) announced positive top line results from a Phase II clinical trial of the oral tablet formulation of VK2735, demonstrating statistically significant reductions in body weight compared with placebo.
- The company initiated a Phase III VANQUISH Obesity program, which is progressing well with enrollment expected to complete soon.
- VK2735 was shown to be safe and well tolerated in both subcutaneous and oral formulations, with most adverse events categorized as mild or moderate.
- Viking Therapeutics Inc (VKTX) has a strong cash position with $715 million, which supports the completion of planned Phase III obesity trials and further development of additional programs.
- The company is advancing a novel maintenance dosing study for VK2735, exploring various dosing regimens to maintain weight loss, which could enhance long-term treatment adherence.
- Viking Therapeutics Inc (VKTX) reported a significant increase in net loss for the third quarter of 2025, primarily due to increased research and development expenses.
- Research and development expenses rose sharply to $90 million for the quarter, compared to $22.8 million in the same period in 2024.
- The company experienced a decrease in cash, cash equivalents, and short-term investments from $903 million at the end of 2024 to $715 million by September 30, 2025.
- There is uncertainty regarding the timing of an end of Phase II meeting with the FDA, which could impact the progression of the oral VK2735 program.
- The company faces challenges in determining the optimal dosing regimen for VK2735, particularly in transitioning from subcutaneous to oral formulations.
Welcome to the Viking Therapeutics third quarter 2025 financial results conference call. (Operator Instructions) As a reminder, this conference call is being recorded today, October 22, 2025.
I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.
Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that comments made during this conference call today, October 22, 2025, and will contain forward-looking statements under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, time lines and milestones.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
